MDxHealth SA (NASDAQ:MDXH) Short Interest Down 18.3% in April

MDxHealth SA (NASDAQ:MDXH - Get Free Report) saw a large decrease in short interest in April. As of April 15th, there was short interest totalling 27,300 shares, a decrease of 18.3% from the March 31st total of 33,400 shares. Based on an average trading volume of 75,500 shares, the short-interest ratio is currently 0.4 days. Currently, 0.1% of the company's stock are sold short.

MDxHealth Stock Up 1.7 %

Shares of NASDAQ:MDXH traded up $0.03 during trading hours on Monday, hitting $1.75. The company's stock had a trading volume of 19,894 shares, compared to its average volume of 82,514. The firm's fifty day moving average price is $1.58 and its 200 day moving average price is $1.86. MDxHealth has a 52 week low of $1.35 and a 52 week high of $3.50. The company has a market capitalization of $82.75 million, a price-to-earnings ratio of -1.15 and a beta of 1.32. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45.

MDxHealth (NASDAQ:MDXH - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.07. The company had revenue of $24.74 million during the quarter, compared to the consensus estimate of $22.67 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. As a group, research analysts expect that MDxHealth will post -1.15 EPS for the current year.

Hedge Funds Weigh In On MDxHealth

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FAS Wealth Partners Inc. boosted its holdings in shares of MDxHealth by 49.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company's stock valued at $58,000 after buying an additional 8,100 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in MDxHealth by 100.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company's stock valued at $47,000 after acquiring an additional 10,000 shares in the last quarter. Geode Capital Management LLC purchased a new position in MDxHealth in the fourth quarter worth $25,000. XTX Topco Ltd acquired a new position in shares of MDxHealth during the fourth quarter worth $63,000. Finally, Castleview Partners LLC purchased a new stake in shares of MDxHealth during the 1st quarter valued at $48,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.